Combination of skin-directed therapy and oral etoposide for smoldering adult T-cell leukemia/lymphoma with skin involvement

References

• Uchiyama T, Yodoi J, Sagawa K, . Adult T-cell leukemia:clinical and hematologic features of 16 cases. Blood 1977;50:481–492.
   PubMed Web of Science ®Google Scholar
• Poiesz BJ, Ruscetti FW, Gazdar AF, . Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415–7419.
   PubMed Web of Science ®Google Scholar
• Blattner WA.Human retroviruses: their role in cancer. Proc Assoc Am Physicians 1999;111:563–572.
   PubMedGoogle Scholar
• Edlich RF, Arnette JA, Williams FM.Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000;18:109–119.
   PubMed Web of Science ®Google Scholar
• Shimoyama M.Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991;79:428–437.
   PubMed Web of Science ®Google Scholar
• Setoyama M, Katahira Y, Kanzaki T.Clinicopathologic analysis of 124 cases of adult T-cell leukemia/lymphoma with cutaneous manifestations:the smouldering type with skin manifestations has a poorer prognosis than previously thought. J Dermatol 1999;26:785–790.
   PubMedGoogle Scholar
• Sawada Y, Hino R, Hama, K, . The type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011;117:3961–3967.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Hermine O, Bazarbachi A, . Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009;27:453–459.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Matsumoto T, Ohtsubo H, . Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma 1999;36:67–75.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Miyoshi I, Hinuma Y.Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982;79:2031–2035.
   PubMed Web of Science ®Google Scholar
• Yamada Y.Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood 1983;61:192–199.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Ikeda S, Murata K, . Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leuk Res 1993;17:157–166.
   PubMed Web of Science ®Google Scholar
• Shimauchi T, Sugita K, Nishio D, . Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides. J Dermatol Sci 2008;50:217–225.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109–3115.
   PubMed Web of Science ®Google Scholar
• Takasaki Y, Iwanaga M, Imaizumi Y, . Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010;115:4337–4343.
   PubMed Web of Science ®Google Scholar
• Gathers RC, Scherschun L, Malick F, . Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol 2002;47:191–197.
   PubMed Web of Science ®Google Scholar
• Diederen PV, van Weelden H, Sanders CJ, . Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003;48:215–219.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Ohshima K, Karube K, . Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/lymphoma. Br J Dermatol 2005;152:76–81.
   PubMed Web of Science ®Google Scholar
• Radice PA, Bunn PA Jr, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell cancer. non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 1979;63:1231–1239.
   PubMedGoogle Scholar
• Vogelzang NJ, Raghavan D, Kennedy BJ.VP-16-213 (etoposide): the mandrake root from Issyk-Kul. Am J Med 1982;72:136–144.
   PubMed Web of Science ®Google Scholar
• Loike JD, Horwitz SB.Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 1976;15:5443–5448.
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Ross WE.DNA damage as a basis for 4’-demethylepipodophyllotoxin-9-(4.6-O-ethylidene-t)-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 1983;43:120–124.
   PubMed Web of Science ®Google Scholar
• Ezoe A, Kohda K, Hirayama Y, . [Two cases of adult T-cell leukemia/lymphoma with long-term remission by chronic daily administration of low-dose etoposide]. Gan To Kagaku Ryoho 1995;22:547–552.
   PubMedGoogle Scholar
• Xinjia F, Matano S, Amitani S, . [Low-dose etoposide in a patient with adult T-cell leukemia/lymphoma who had severe complications]. Gan To Kagaku Ryoho 2001;28:1269–1272.
   PubMedGoogle Scholar
• Ikawa Y, Kanehara T, Takata M, . [Hypercalcemia due to maculopapular type adult T-cell leukemia/lymphoma]. Clin Dermatol 2005;47:381–384.
   Google Scholar
• Stadtmauer EA, Casselith PA, Gale RP.Etoposide in leukemia, lymphoma and bone marrow transplantation. Leuk Res 1989;13:639–650.
   PubMed Web of Science ®Google Scholar